This company isn't going anywhere and has partnerships with some of the biggest names in the bio/pharm industry. Not to mention the drug ILUVIEN that was delayed in the US is already been approved in many other Countries. We will close over $2.756 today and then a slow climb back to $4. Long term this is a winner!!